JNJJanssen Research & Development, LLCRunning, no new patients
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Hematological Malignancies
12Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Nov 2021, none posted yet
Counts until it's fixed
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score12
Score over time
- Stage
- Phase 2
- Patients
- 194 (final count)
- Started
- Sep 17, 2020
- Main results expected
- Nov 9, 2021
- Fully finished
- May 28, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohorts A and C: Overall Response Rate (ORR)
Measured over: Up to 2.9 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2021-11-09, no fading
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04557098 · record last updated 2026-07-31 · checked 2026-11-09 15:47 UTC